Recce Ltd (ASX:RCE) has been granted a trading halt by the ASX pending the receipt of information from the United States Food and Drug Administration (FDA) following Recce’s recent data submission.
Recce is focused on the development of a new class of synthetic antibiotics.
The halt will remain in place until the opening of trade on Thursday 16th November 2017, or earlier if an announcement is made to the market.